AngioDynamics, Inc. (NASDAQ:ANGO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have earned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $18.6667.

ANGO has been the topic of a number of analyst reports. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Finally, Canaccord Genuity Group cut their price objective on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, April 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANGO. Farther Finance Advisors LLC lifted its holdings in shares of AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 1,199 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics in the fourth quarter valued at about $27,000. State of Wyoming purchased a new position in AngioDynamics in the second quarter valued at about $31,000. Russell Investments Group Ltd. lifted its stake in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 4,268 shares in the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Trading Down 0.2%

Shares of AngioDynamics stock traded down $0.02 during mid-day trading on Tuesday, hitting $12.96. 105,385 shares of the stock were exchanged, compared to its average volume of 468,282. The stock has a market capitalization of $535.34 million, a price-to-earnings ratio of -17.27 and a beta of 0.34. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $13.99. The company has a 50-day simple moving average of $11.84 and a 200 day simple moving average of $11.34.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.